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Resumo
Apresentamos o caso de um homem de 71 
anos com icterícia colestática inaugural, com 
estenose e espessamento parietal circunferencial 
do colédoco distal, assim como uma massa 
infiltrativa hepática condicionando “amputação” 
das vias biliares dilatadas à periferia. O doente foi 
submetido a pancreatoduodenectomia e hemi-
hepatectomia por suspeita de colangiocarcinoma. 
A histologia revelou tratar-se de colangite e 
pseudotumor inflamatório hepático (PIH) 
associados a IgG4.
A doença associada a IgG4 (DA-IgG4) foi 
recentemente estabelecida como uma condição 
sistémica, em que ocorrem infiltrados fibro-
inflamatórios e tumefação de um ou mais órgãos. 
As manifestações hepatobiliares incluem a 
colangite e o PIH associados a IgG4 – que fazem 
diagnóstico diferencial com colangiocarcinoma. 
Os médicos devem estar familiarizados com 
esta patologia, normalmente responsiva à 
corticoterapia, para evitar procedimentos 
invasivos desnecessários.
Os autores apresentam um caso de colangite e 
PIH associados a IgG4 e fazem uma revisão da 
literatura desta rara apresentação de DA-IgG4.
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Abstract
We report the case of  a 71-year-old man presenting 
inaugural cholestatic jaundice, with a stricture 
and circumferential wall thickening of  the distal 
common bile duct, as well as an ill-defined hepatic 
infiltrative mass with “amputation” of  peripheral 
distended bile ducts. The patient underwent a 
pancreaticoduodenectomy and hemihepatectomy 
for suspected cholangiocarcinoma. Histology 
revealed IgG4 associated cholangitis (IgG4-AC) 
and hepatic pseudoinflammatory tumour (HPT).
IgG4-related disease (IgG4-RD) is a recently 
established systemic disease, characterized 
by fibro-inflammatory tissue infiltrates and 
tumefaction of  one or more organs. The 
hepatobiliary manifestations comprise IgG4-AC 
and associated HTP - which can be mistaken 
for cholangiocarcinoma. Clinicians must be 
familiar with this disorder, usually responsive 
to corticosteroid therapy, in order to avoid 
unnecessary invasive procedures.
We present a case of  IgG4-AC and associated 
HTP and review the literature of  this rare 
presentation of  IgG4-RD.
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Radiological Case Report / Caso Clínico
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a systemic 
condition affecting virtually every organ system that comprises 
common pathologic, serologic and clinical features. It has been 
increasingly recognized since 2003, when Kamisawa et al1 
proposed that a group of  disorders, previously thought to be 
unrelated, might be part of  a broader spectrum of  IgG4-RD; 
nevertheless, pathogenesis is still poorly understood. Common 
features include tissue infiltration by IgG4-positive plasma cells 
and lymphocytes, as well as a variable degree of  fibrosis and 
tumour-like swelling in one or more organs.2,3 Symptoms are 
mild, with neither fever nor elevation of  C-reactive protein 
levels. Diagnosis requires meticulous correlation of  the 
histopathologic features with clinical and radiologic findings. 
Imaging plays an important role in demonstrating enlargement 
of  involved organs, detecting multiorgan involvement and, 
eventually, for assessing response to therapy.
Clinical Case
We report the case of  a 71-year-old man who presented 
himself  at the emergency department of  our hospital 
in August 2015 complaining of  abdominal pain for the 
previous week, jaundice, choluria and diarrhea with acholic 
faeces. At physical examination, the abdomen was tender at 
the epigastrium and right upper abdomen. The patient had 
a previous clinical history of  bladder neoplastic polyps (low 
grade papillary urethral non-invasive carcinoma) removed 
by transurethral resection in 2008 and 2010, diabetes 
mellitus type 2, arterial hypertension and vascular peripheral 
disease and he was regularly medicated with metformin and 
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vildagliptin, enalapril and hydrochlorothiazide, diosmin and 
esomeprazole. 
Blood tests at admission showed high levels of  total 
bilirubin 9.90mg/dL (<1.2mg/dL) with a predominant 
increase of  the direct bilirubin (conjugated component), 
as well as high levels of  alanine aminotransferase 116mg/
dL (12-78mg/dL), aspartate aminotransferase 122mg/
dL (<34mg/dL), gamma-glutamyl transferase 1330mg/
dL (<73mg/dL), alkaline phosphatase 880mg/dL (40-
130mg/dL); slightly elevated C-reactive protein 0.9mg/dL 
(<0.5mg/dL); abnormal presence of  moderate quantity of  
bilirubin in urine analysis; low levels of  amylase (3 U/L) 
and haemoglobin of  11.8 mg/dL (13-17.5mg/dL). Further 
workup, during the hospital stay, revealed normal levels of  
the tumour markers CEA of  1.9mg/dL (<5mg/dL) and 
CA 19.9 of  23.4mg/dL (0-37mg/dL), as well as further 
progressive increase of  total bilirubin level.
An abdominal ultrasound was performed at admission (Fig. 
1), which revealed bilateral dilatation of  the intrahepatic 
biliary ducts, as well as the proximal half  of  the common bile 
duct (CBD), with stenosis and a significant hipoechogenic 
circumferential wall thickening of  the remaining CBD; 
non distended gallbladder, without signs of  cholelithiasis; 
diffuse atrophy of  the pancreatic parenchyma and mild 
dilatation of  the main pancreatic duct. 
A computed tomography (CT) was performed subsequently 
(Fig. 2), confirming the previous findings of  biliary ducts 
dilatation (CBD calibre of  19mm), with stenosis and a 
significant circumferential and regular wall thickening of  
the distal common bile duct, with homogeneous contrast 
enhancement; also, diffuse atrophy of  the pancreatic 
parenchyma, with some calcific foci, mild diffuse dilatation 
(4-5mm) and slight irregularity of  the main pancreatic duct 
(suggestive of  chronic pancreatitis). These findings were 
Figure 1 – Ultrasound. (A) Axial plane, showing 
bilateral dilatation of  the intra-hepatic biliary ducts 
(arrows). (B) Axial plane and (C) sagittal plane, 
demonstrating dilatation of  the proximal CBD 
(arrow), with stenosis and hipoechogenic circum-
ferential wall thickening of  the remaining CBD 
(open arrows). (D) Axial plane, showing diffuse 
atrophy of  the pancreatic parenchyma and mild 
dilatation of  the main pancreatic duct (arrows). 
It was also noticed moderate hepatomegaly with 
signs of  steatosis and minor splenomegaly.
Figure 2 – Enhanced computed tomography 
(CT). (A) Axial plane in a liver dedicated window, 
depicting a poorly circumscribed area of  hetero-
geneity on segment II of  the left liver lobe, with 
mild delayed enhancement (open arrows), causing 
“amputation” of  peripheral dilated intra-hepatic 
bile ducts (arrows). Axial plane at a higher level (B) 
and a lower level (C), as well as coronal plane (D), 
demonstrating dilatation of  the bile ducts (arrows), 
with stenosis and a significant circumferential and 
regular wall thickening of  the distal CBD, with ho-
mogeneous contrast enhancement (open arrows). 
Also, notice the diffuse atrophy of  the pancreatic 
parenchyma, with some calcific foci, and mild 
diffuse dilatation and slight irregularity of  the main 
pancreatic duct.
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not present on a previous CT (dated from September 
2014). The magnetic resonance cholangiopancreatography, 
also confirmed the previous findings and further revealed 
an area of  left hepatic parenchyma heterogeneity with 
ill-defined margins at segment II, presenting mild 
hiperintensity at T2-weighted images (WI) and hipointensity 
at T1-WI, associated with “amputation” of  peripheral 
dilated intrahepatic bile ducts and an altered luminal signal 
intensity (hipointensity at T2-WI and hiperintensity at T1-
WI) in the proximal dilated bile ducts. Retrospectively, a 
corresponding ill-defined infiltrative mass, with a mild 
delayed enhancement, was also depicted on CT. 
Based on the clinical and imaging elements, a presumptive 
diagnosis of  multifocal cholangiocarcinoma was made. 
Since no alternative diagnosis was proposed, biopsy was not 
performed and the patient underwent surgery. A cephalic 
pancreaticoduodenectomy and a left hemihepatectomy 
were performed. The pathological findings were highly 
suggestive of  IgG4-related disease, with IgG4 associated 
cholangitis (IgG4-AC) and a hepatic pseudoinflammatory 
tumour (with approximately 4cm), probably related to 
a focal IgG4-AC exacerbation; no neoplastic tissue was 
found. Ensuing blood tests revealed IgG values of  2160 
md/dL, but the IgG4 serum levels were not subsequently 
assessed.
The post-operative course was complicated by a 
surgical wound infection, a fluid collection adjacent to 
the jejunopancreatic anastomosis with fistulisation to 
the skin in the right upper abdomen, another infected 
haematic collection in the left upper abdomen, as well 
as a left empyema, that required intravenous broad 
spectrum antibiotics and percutaneous drainage. Except 
for the surgical wound infection, these complications were, 
eventually, managed after a long course of  conservative 
treatment and the patient was discharged home 39 days 
after surgery. The surgical wound infection went on for 
several months, postponing the beginning of  treatment 
with systemic corticosteroids. 
Discussion
The hepatobiliary manifestations of  IgG4-related disease 
(IgG4-RD) comprise cholangitis, pseudoinflammatory 
tumour and IgG4 hepatopathy.3
After the pancreas, the bile ducts are the second most 
commonly involved organ, seen in up to 88% of  patients 
with IgG4-RD.3 IgG4-associated cholangitis (IgG4-AC) 
occurs more frequently in patients with type 1 autoimmune 
pancreatitis (60-70%), but it might also occur without 
pancreatic involvement, making the diagnosis more 
Figure 3 – Magnetic resonance (MR). T2-weighted image 
(WI) (A), T2-WI with fat suppression (B) and T1-WI 
(C) showing at the level of  hepatic segment II an area of  
parenchyma heterogeneity, with mild hiperintensity on 
T2-WI and hipointensity on T1-WI, and peripheral dilated 
intra-hepatic bile ducts with an altered luminal signal 
intensity. T2-WI (D), (E) and (F) showing dilatation of  the 
proximal half  of  the CBD with stenosis and thickening of  
the distal CBD (open arrows). (G) MR cholangiography, 
showing the dilated bile ducts until the point of  stenosis 
in the CBD (open arrow); and a defect in the intra-hepatic 
bile ducts at hepatic segment II (arrows), corresponding to 
the area of  parenchyma heterogeneity. 
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difficult.4,5 Involvement by other extrapancreatic lesions 
may be additionally seen.2,6 Generally, IgG4-AC affects 
older patients and can induce obstructive jaundice.5 
Both intra- and extrahepatic segments can be affected by 
dense bile duct infiltration of  IgG4-positive plasma cells 
and extensive fibrosis, but the most commonly involved 
segment is the intrapancreatic portion of  the common bile 
duct (CBD). The typical imaging appearance, at MRCP, is 
focal or diffuse bile duct wall thickening - usually long and 
continuous strictures are depicted - mostly associated with 
stenosis and upstream dilatation.7 Isolated strictures of  the 
distal CBD may also occur.8 CT and MR imaging usually 
depict a circular and symmetric ring of  tissue encasing 
the bile duct wall, with relatively smooth margins and 
homogeneous enhancement in the delayed phase. 
The main differential diagnoses are cholangiocarcinoma 
and primary sclerosing cholangitis (PSC). The latter 
would not be expected in this case due to the acute onset 
of  symptoms, older age and no previous history of  
inflammatory bowel disease; also, the typical findings for 
PSC are multifocal and short intrahepatic biliary strictures 
with beaded or “pruned-tree” appearance.5,8 Differentiation 
from cholangiocarcinoma may be difficult, especially in the 
presence of  a soft-tissue mass that produces stenosis of  
the hilar hepatic bile duct, presented as inaugural jaundice. 
In the case of  cholangiocarcinoma,  tumour infiltration 
is usually confined to either extrahepatic or intrahepatic 
bile ducts, whereas in IgG4-AC luminal irregularities and 
stenosis generally involve both the biliary and pancreatic 
ducts.2,9 Differentiating hilar cholangiocarcinoma from 
other causes of  hilar obstruction remains an issue.6 There 
are a few reports in the literature addressing cases of  
IgG4-cholangitis of  the CBD, with no apparent pancreatic 
involvement, that underwent surgery for suspected 
cholangiocarcinoma.6,10-12
IgG4 related cholangitis and hepatic inflammatory 
pseudotumour (HIP) is an extremely rare association, 
in which the cholangitis is considered either as the 
condition preceding or associated with the inflammatory 
pseudotumour.13 Inflammatory pseudotumours occur 
most commonly in the lung and only occasionally in 
extrapulmonary organs, including the liver in about 8% 
of  cases.14 Inflammatory pseudotumours are characterised 
histologically by the proliferation of  fibroblasts 
or myofibroblasts and inflammatory cell infiltrate, 
independently of  the organs where they occur. Infections 
and autoimmune reactions have been suggested as possible 
triggers, although pathogenesis of  hepatic inflammatory 
pseudotumours is still incompletely understood and 
might differ among cases.14 On CT, homogeneous delayed 
enhancement was considered an important diagnostic 
imaging characteristic of  IgG4-related disease. On MRI, 
these lesions are typically hypointense on T1-WI and 
hyperintense on T2-WI, but contrast enhancement patterns 
are variable.15 The differential diagnosis is generally with a 
primary liver neoplasm or metastasis, if  the bile ducts or 
pancreas are also involved by the inflammatory disease.
The IgG4-RD usually demonstrates a favourable 
response to corticosteroid therapy. However, it is strongly 
recommended to confirm the diagnosis of  IgG4-RD by 
a biopsy specimen instead of  a steroid trial, since some 
patients are refractory to such therapy and some malignant 
lesions may improve after steroid treatment. Relapses may 
sometimes occur, even under maintenance of  corticosteroid 
therapy;7,12 azathioprine is frequently used in these cases.10
In the case we present, there was a lymphoplasmacytic 
infiltrate enriched in IgG4-positive plasma cells at histology, 
involving both the intra- and extrahepatic bile ducts. 
However, at imaging, no luminal irregularities or stenosis of  
the intrahepatic bile ducts were seen, but only a dominant 
stricture of  the distal CBD causing upstream dilatation. 
This showed typical circumferential regular thickening of  
the wall and homogeneous enhancement. There were also 
pancreatic findings of  chronic pancreatitis (confirmed at 
histology). Additionally, a probable exacerbation of  the 
cholangitis at the left hepatic lobe caused a “mass-like” 
appearance, related to an inflammatory pseudotumour. The 
finding of  a hepatic “mass” coupled with CBD stenosis 
and thickening with upstream dilatation may mimic 
multifocal cholangiocarcinoma, which represents about 5% 
of  cholangiocarcinomas.16 The associated presentation of  
IgG4-AC and HPT is extremely rare and was misleading. 
The older age of  the patient and the inaugural presentation 
with obstructive jaundice did not help in establishing 
the differential diagnosis. Furthermore, tumour markers 
CA 19.9 and CEA are not elevated in 15% and 70% of  
cholangiocarcinomas, respectively.16 
In conclusion, differentiating IgG4-related hepatobiliary 
disease from cholangiocarcinoma remains a challenge. 
Altogether, we believe that this was an extremely difficult 
case to differentiate from cholangiocarcinoma, based on 
clinical presentation and imaging alone. Therefore, we 
expect to emphasize the need for a biopsy specimen before 
potentially harmful and unnecessary invasive procedures 
are undertaken. Moreover, we suggest regular testing on 
IgG4 blood levels when there are overlapping hepatobiliary 
imaging findings, bearing in mind that it is neither specific 
nor uniformly increased in all patients, but it might guide 
clinicians into the right track for IgG4-RD diagnosis.
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